VERTEX PHARMACEUTICALS INC / MA (VRTX)

A forensic read on VERTEX PHARMACEUTICALS INC / MA built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, primarily generating revenue from its cystic fibrosis (CF) treatments, with new approvals in sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. Revenue GREW significantly from $3.05 billion in FY2018 to $12.00 billion in FY2025, while net margin compressed from 68.8% to 32.9% over the same period.

← Browse all forensic stock analyses

Data from SEC EDGAR public filings. Forensic signals flag probability, not certainty.